Cluster Health & Mission Cancer Brokerage Event

28 Sept 2026 | Brussels, Belgium

Register
Register
Register

Project cooperationUpdated on 6 August 2026

(DISEASE-14) GMP/IMP supply and early-phase trial delivery for neurodegenerative-disease interventions

EU Grants and Funding Coordinator at Elpen Pharmaceutical Co. Inc.

Athens, Greece

About

ELPEN Pharmaceutical and its affiliated Athens LifeTech Park (Greece) offer manufacturing and trial-delivery capability to HORIZON-HLTH-2027-02-DISEASE-14.

Where the intervention's active substance requires manufacturing, ELPEN can produce and release the investigational medicinal product (IMP) to GMP standard, provide formulation/dosage-form development, and support trial conduct, regulatory pathway and pharmacovigilance.

Via Athens LifeTech Park, the group delivers Phase 1/2 trials through its early-phase clinical CRO (Phase 0–II) with Greek/EU site management and registry-powered recruitment, and provides bioanalysis/PK (LC-MS/MS) and molecular biomarker measurement (qPCR, protein analysis).

Note: ELPEN/ALTP is a manufacturing and trial-delivery partner, not a neurodegenerative-disease specialist, and does not own a candidate intervention or provide imaging/omics/AI capability. We are therefore seeking a clinical/scientific lead with the candidate intervention and neuro expertise. ALTP's incubator can bring qualifying SMEs.

Topic

  • Clinical trials: HORIZON-HLTH-2027-02-DISEASE-14-two-stage Clinical trials for advancing innovative interventions for neurodegenerative diseases

Organisation

Elpen Pharmaceutical Co. Inc.

Company (Industry)

Athens, Greece

Similar opportunities